c-Myc or Cyclin D1 Mimics Estrogen Effects on Cyclin E-Cdk2 Activation and Cell Cycle Reentry

REFERENCES

• Adams, P. D., W. R. Sellers, S. K. Sharma, A. D. Wu, C. M. Nalin, Kaelin W., Jr. 1996. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol. Cell. Biol. 16: 6623–6633.
   PubMed Web of Science ®Google Scholar
• Altucci, L., R. Addeo, L. Cicatiello, S. Dauvois, M. G. Parker, M. Truss, M. Beato, V. Sica, F. Bresciani, and A. Weisz 1996. 17β-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G1-arrested human breast cancer cells. Oncogene 12: 2315–2324.
   PubMed Web of Science ®Google Scholar
• Aprelikova, O., Y. Xiong, and E. T. Liu 1995. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J. Biol. Chem. 270: 18195–18197.
   PubMed Web of Science ®Google Scholar
• Cobrinik, D., P. Whyte, D. S. Peeper, T. Jacks, and R. A. Weinberg 1993. Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev. 7: 2392–2404.
   PubMed Web of Science ®Google Scholar
• Daksis, J. I., R. Y. Lu, L. M. Facchini, W. W. Marhin, and L. J. Penn 1994. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene 9: 3635–3645.
   PubMed Web of Science ®Google Scholar
• Daly, R. J., W. H. Harris, D. Y. Wang, and P. D. Darbre 1991. Autocrine production of insulin-like growth factor II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells. Cell Growth Differ. 2: 457–464.
   PubMedGoogle Scholar
• De Azevedo, W. F., S. Leclerc, L. Meijer, L. Havlicek, M. Strnad, and S. H. Kim 1997. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243: 518–526.
   PubMedGoogle Scholar
• deFazio, A., Y.-E. Chiew, M. McEvoy, C. K. W. Watts, and R. L. Sutherland 1997. Antisense estrogen receptor RNA expression increases epidermal growth factor receptor expression in breast cancer cells. Cell Growth Differ. 8: 903–911.
   PubMedGoogle Scholar
• De Luca, A., T. K. MacLachlan, L. Bagella, C. Dean, C. M. Howard, P. Paolo Claudio, A. Baldi, K. Khalili, and A. Giordano 1997. A unique domain of pRb2/p130 acts as an inhibitor of Cdk2 kinase activity. J. Biol. Chem. 272: 20971–20974.
   PubMed Web of Science ®Google Scholar
• Dubik, D., T. C. Dembinski, and R. P. C. Shiu 1987. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res. 47: 6517–6521.
   PubMed Web of Science ®Google Scholar
• Fantl, V., G. Stamp, A. Andrews, I. Rosewell, and C. Dickson 1995. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 9: 2364–2372.
   PubMed Web of Science ®Google Scholar
• Foster, J. S., and J. Wimalasena 1996. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol. Endocrinol. 10: 488–498.
   PubMedGoogle Scholar
• Gu, Y., J. Rosenblatt, and D. O. Morgan 1992. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J. 11: 3995–4005.
   PubMed Web of Science ®Google Scholar
• Haas, K., P. Staller, C. Geisen, J. Bartek, M. Eilers, and T. Moroy 1997. Mutual requirement of Cdk4 and Myc in malignant transformation: evidence for cyclin D1/Cdk4 and p16INK4A as upstream regulators of Myc. Oncogene 15: 179–192.
   PubMed Web of Science ®Google Scholar
• Hauser, P. J., D. Agrawal, B. Chu, and W. J. Pledger 1997. p107 and p130 associated cyclin A has altered substrate specificity. J. Biol. Chem. 272: 22954–22959.
   PubMedGoogle Scholar
• Henderson, B., R. Ross, and L. Bernstein 1988. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res. 48: 246–253.
   PubMed Web of Science ®Google Scholar
• Henriksson, M., and B. Luscher 1996. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv. Cancer Res. 68: 109–182.
   PubMed Web of Science ®Google Scholar
• Hermeking, H., J. O. Funk, M. Reichert, J. W. Ellwart, and D. Eick 1995. Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21WAF1/CIP1/SDI1. Oncogene 11: 1409–1415.
   PubMedGoogle Scholar
• Huang, T. S., J. Duyster, and J. Y. Wang 1995. Biological response to phorbol ester determined by alternative G1 pathways. Proc. Natl. Acad. Sci. USA 92: 4793–4797.
   PubMedGoogle Scholar
• Jansen-Durr, P., A. Meichle, P. Steiner, M. Pagano, K. Finke, J. Botz, J. Wessbecher, G. Draetta, and M. Eilers 1993. Differential modulation of cyclin gene expression by MYC. Proc. Natl. Acad. Sci. USA 90: 3685–3689.
   PubMed Web of Science ®Google Scholar
• Kitagawa, M., H. Higashi, H. K. Jung, I. Suzuki-Takahashi, M. Ikeda, K. Tamai, J. Kato, K. Segawa, E. Yoshida, S. Nishimura, and Y. Taya 1996. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J. 15: 7060–7069.
   PubMed Web of Science ®Google Scholar
• Koff, A., F. Cross, A. Fisher, J. Schumacher, K. Leguellec, M. Philippe, and J. M. Roberts 1991. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 66: 1217–1228.
   PubMed Web of Science ®Google Scholar
• Leung, B. S., and A. H. Potter 1987. Mode of estrogen action on cell proliferation in CAMA-1 cells. II. Sensitivity of G1 phase population. J. Cell. Biochem. 34: 213–225.
   PubMed Web of Science ®Google Scholar
• Li, Y., C. Graham, S. Lacy, A. M. Duncan, and P. Whyte 1993. The adenovirus E1A-associated 130-kD protein is encoded by a member of the retinoblastoma gene family and physically interacts with cyclins A and E. Genes Dev. 7: 2366–2377.
   PubMed Web of Science ®Google Scholar
• Lippman, M. E., and G. Bolan 1975. Oestrogen-responsive human breast cancer in long term tissue culture. Nature (London) 256: 592–593.
   PubMed Web of Science ®Google Scholar
• Lukas, J., J. Bartkova, and J. Bartek 1996. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D–cyclin-dependent kinase–pRb-controlled G1 checkpoint. Mol. Cell. Biol. 16: 6917–6925.
   PubMed Web of Science ®Google Scholar
• Mayol, X., J. Garriga, and X. Grana 1995. Cell cycle-dependent phosphorylation of the retinoblastoma-related protein p130. Oncogene 11: 801–808.
   PubMed Web of Science ®Google Scholar
• Mayol, X., J. Garriga, and X. Grana 1996. G1 cyclin/CDK-independent phosphorylation and accumulation of p130 during the transition from G1 to G0 lead to its association with E2F-4. Oncogene 13: 237–246.
   PubMedGoogle Scholar
• Meijer, L., A. Borgne, O. Mulner, J. P. Chong, J. J. Blow, N. Inagaki, M. Inagaki, J. G. Delcros, and J. P. Moulinoux 1997. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243: 527–536.
   PubMedGoogle Scholar
• Moberg, K., M. A. Starz, and J. A. Lees 1996. E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol. Cell. Biol. 16: 1436–1449.
   PubMed Web of Science ®Google Scholar
• Morgan, D. O. 1995. Principles of CDK regulation. Nature (London) 374: 131–134.
   PubMed Web of Science ®Google Scholar
• Murphy, L. J., L. C. Murphy, and H. G. Friesen 1987. Estrogen induction of N-myc and c-myc proto-oncogene expression in the rat uterus. Endocrinology 120: 1882–1888.
   PubMedGoogle Scholar
• Musgrove, E. A., C. S. L. Lee, M. F. Buckley, and R. L. Sutherland 1994. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc. Natl. Acad. Sci. USA 91: 8022–8026.
   PubMed Web of Science ®Google Scholar
• Musgrove, E. A., B. Sarcevic, and R. L. Sutherland 1996. Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for CDK2 activation and pRB hyperphosphorylation. J. Cell. Biochem. 60: 363–378.
   PubMed Web of Science ®Google Scholar
• Ohtsubo, M., A. M. Theodoras, J. Schumacher, J. M. Roberts, and M. Pagano 1995. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol. Cell. Biol. 15: 2612–2624.
   PubMed Web of Science ®Google Scholar
• Perez-Roger, I., D. L. Solomon, A. Sewing, and H. Land 1997. Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes. Oncogene 14: 2373–2381.
   PubMed Web of Science ®Google Scholar
• Philipp, A., A. Schneider, I. Vasrik, K. Finke, Y. Xiong, D. Beach, K. Alitalo, and M. Eilers 1994. Repression of cyclin D1: a novel function of MYC. Mol. Cell. Biol. 14: 4032–4043.
   PubMed Web of Science ®Google Scholar
• Pines, J. 1995. Cyclins and cyclin-dependent kinases: a biochemical view. Biochem. J. 308: 697–711.
   PubMed Web of Science ®Google Scholar
• Planas-Silva, M. D., and R. A. Weinberg 1997. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell. Biol. 17: 4059–4069.
   PubMed Web of Science ®Google Scholar
• Polyak, K., M.-H. Lee, H. Erdjument-Bromage, A. Koff, J. M. Roberts, P. Tempst, and J. Massagué 1994. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59–66.
   PubMed Web of Science ®Google Scholar
• Prall, O. W. J. Unpublished data.
   Google Scholar
• Prall, O. W. J., B. Sarcevic, E. A. Musgrove, C. K. W. Watts, and R. L. Sutherland 1997. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J. Biol. Chem. 272: 10882–10894.
   PubMed Web of Science ®Google Scholar
• Pusch, O., G. Bernaschek, M. Eilers, and M. Hengstschlager 1997. Activation of c-Myc uncouples DNA replication from activation of G1-cyclin dependent kinases. Oncogene 15: 649–656.
   PubMedGoogle Scholar
• Quelle, D. E., R. A. Ashmun, S. A. Shurtleff, J.-Y. Kato, D. Bar-Sagi, M. F. Roussel, and C. J. Sherr 1993. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 7: 1559–1571.
   PubMed Web of Science ®Google Scholar
• Resnitzky, D., M. Gossen, H. Bujard, and S. I. Reed 1994. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol. Cell. Biol. 14: 1669–1679.
   PubMed Web of Science ®Google Scholar
• Riley, D. J., E. Y.-H. P. Lee, and W.-H. Lee 1994. The retinoblastoma protein: more than a tumor suppressor. Annu. Rev. Cell Biol. 10: 1–29.
   PubMedGoogle Scholar
• Roussel, M. F., A. M. Theodoras, M. Pagano, and C. J. Sherr 1995. Rescue of defective mitogenic signaling by D-type cyclins. Proc. Natl. Acad. Sci. USA 92: 6837–6841.
   PubMed Web of Science ®Google Scholar
• Rudolph, B., R. Saffrich, J. Zwicker, B. Henglein, R. Muller, W. Ansorge, and M. Eilers 1996. Activation of cyclin-dependent kinases by Myc mediates induction of cyclin A, but not apoptosis. EMBO J. 15: 3065–3076.
   PubMed Web of Science ®Google Scholar
• Sherr, C. J. 1993. Mammalian G1 cyclins. Cell 73: 1059–1065.
   PubMed Web of Science ®Google Scholar
• Sherr, C. J. 1995. D-type cyclins. Trends Biochem. Sci. 20: 187–190.
   PubMed Web of Science ®Google Scholar
• Sherr, C. J., and J. M. Roberts 1995. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9: 1149–1163.
   PubMed Web of Science ®Google Scholar
• Shiyanov, P., S. Bagchi, G. Adami, J. Kokontis, N. Hay, M. Arroyo, A. Morozov, and P. Raychaudhuri 1996. p21 disrupts the interaction between cdk2 and the E2F-p130 complex. Mol. Cell. Biol. 16: 737–744.
   PubMedGoogle Scholar
• Sicinski, P., J. L. Donaher, S. B. Parker, T. Li, A. Fazeli, H. Gardner, S. Z. Haslam, R. T. Bronson, S. J. Elledge, and R. A. Weinberg 1995. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82: 621–630.
   PubMed Web of Science ®Google Scholar
• Solomon, D. L., A. Philipp, H. Land, and M. Eilers 1995. Expression of cyclin D1 mRNA is not upregulated by Myc in rat fibroblasts. Oncogene 11: 1893–1897.
   PubMedGoogle Scholar
• Soule, H. D., and C. M. McGrath 1980. Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice. Cancer Lett. 10: 177–189.
   PubMed Web of Science ®Google Scholar
• Steiner, P., A. Philipp, J. Lukas, D. Godden-Kent, M. Pagano, S. Mittnacht, J. Bartek, and M. Eilers 1995. Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J. 14: 4814–4826.
   PubMed Web of Science ®Google Scholar
• Sutherland, R. L., R. E. Hall, and I. W. Taylor 1983. Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res. 43: 3998–4006.
   PubMed Web of Science ®Google Scholar
• Sutherland, R. L., R. R. Reddel, and M. D. Green 1983. Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. Eur. J. Cancer Clin. Oncol. 19: 307–318.
   PubMedGoogle Scholar
• Sweeney, K. J., A. Swarbrick, R. L. Sutherland, and E. A. Musgrove 1997. Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells. Oncogene 16: 2865–2878.
   Google Scholar
• Tsai, L. H., E. Lees, B. Faha, E. Harlow, and K. Riabowol 1993. The cdk2 kinase is required for the G1-to-S transition in mammalian cells. Oncogene 8: 1593–1602.
   PubMed Web of Science ®Google Scholar
• Vairo, G., D. M. Livingston, and D. Ginsberg 1995. Functional interaction between E2F-4 and p130: evidence for distinct mechanisms underlying growth suppression by different retinoblastoma protein family members. Genes Dev. 9: 869–881.
   PubMed Web of Science ®Google Scholar
• van den Heuvel, S., and E. Harlow 1993. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262: 2050–2054.
   PubMed Web of Science ®Google Scholar
• Vlach, J., S. Hennecke, K. Alevizopoulos, D. Conti, and B. Amati 1996. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J. 15: 6595–6604.
   PubMed Web of Science ®Google Scholar
• Watson, P. H., R. T. Pon, and R. P. C. Shiu 1991. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res. 51: 3996–4000.
   PubMed Web of Science ®Google Scholar
• Watts, C. K. W., A. Brady, B. Sarcevic, A. deFazio, E. A. Musgrove, and R. L. Sutherland 1995. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol. Endocrinol. 9: 1804–1813.
   PubMedGoogle Scholar
• Weinberg, R. A. 1995. The retinoblastoma protein and cell cycle control. Cell 81: 323–330.
   PubMed Web of Science ®Google Scholar
• Wilcken, N. R. C., O. W. J. Prall, E. A. Musgrove, and R. L. Sutherland 1997. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin. Cancer Res. 3: 849–854.
   PubMedGoogle Scholar
• Wolf, D. A., H. Hermeking, T. Albert, T. Herzinger, P. Kind, and D. Eick 1995. A complex between E2F and the pRb-related protein p130 is specifically targeted by the simian virus 40 large T antigen during cell transformation. Oncogene 10: 2067–2078.
   PubMedGoogle Scholar
• Woo, M. S., I. Sanchez, and B. D. Dynlacht 1997. p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity. Mol. Cell. Biol. 17: 3566–3579.
   PubMed Web of Science ®Google Scholar